Business Context and Reporting Period
Integra LifeSciences Holdings Corporation filed this unaudited Form 10-Q for the quarter and nine months ended September 30, 2023. The company develops and sells medical technologies through two reportable segments: Codman Specialty Surgical (neurosurgery and instruments) and Tissue Technologies (wound reconstruction, surgical reconstruction, nerve repair and related products).
Financial Results and Key Metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Revenue | $382.4 million | $385.2 million | $1,144.5 million | $1,159.6 million |
| Gross margin | 57.1% | 61.5% | 57.5% | 62.1% |
| Operating income | $26.6 million | $65.0 million | $75.5 million | $171.1 million |
| Net income | $19.5 million | $49.9 million | $47.9 million | $127.6 million |
| Diluted EPS | $0.24 | $0.60 | $0.59 | $1.53 |
| Operating cash flow | Not separately provided | Not separately provided | $81.2 million | $179.1 million |
- Q3 revenue declined 0.7%; nine-month revenue declined 1.3% year over year.
- Codman Specialty Surgical revenue increased 7.4% in Q3 and 4.3% for the first nine months. Tissue Technologies revenue declined 15.6% in Q3 and 11.7% for the first nine months.
- Q3 operating margin was approximately 7.0%, compared with 16.9% in the prior-year quarter. Nine-month operating margin was approximately 6.6%, compared with 14.8%.
- Research and development expense increased to $26.6 million in Q3 and $79.9 million for the first nine months. Selling, general and administrative expense increased to $161.9 million and $493.5 million, respectively.
- Cash and cash equivalents were $273.7 million at September 30, 2023, compared with $456.7 million at December 31, 2022. Working capital was $671.5 million, down from $840.6 million.
- Net cash used in financing activities was $223.0 million, principally reflecting $275.0 million of share repurchases, partially offset by $146.9 million of borrowings.
- Total borrowings included $859.8 million under the senior credit facility, $75.7 million under the securitization facility and $569.5 million of long-term convertible securities, based on balance-sheet carrying amounts.
- The company reported $81.2 million of operating cash flow versus $42.3 million of capital expenditures for the first nine months.
Material Changes Versus the Prior Comparable Period
- The Boston manufacturing-facility recall materially reduced Tissue Technologies revenue and profitability. For the first nine months, the company recorded a $19.7 million product-return provision, a $24.6 million inventory write-off and $9.0 million of idle-capacity charges.
- Q3 gross margin decreased 440 basis points, and nine-month gross margin decreased 460 basis points, primarily because of the Boston recall-related costs.
- Reported nine-month operating income fell $95.6 million, while net income fell $79.7 million. The company also incurred $100.9 million of special charges in the first nine months, compared with $38.0 million in the prior-year period.
- Operating cash flow declined $97.9 million year over year, reflecting lower earnings and unfavorable working-capital changes, including increased inventory and other current assets.
- Interest income increased because of higher interest rates, but interest expense also increased modestly. The effective tax rate declined to 8.2% for the first nine months from 14.8%, partly due to prior-year tax-return benefits and lower income in higher-tax jurisdictions.
- The company repurchased $275.0 million of stock through January and August 2023 accelerated share repurchase agreements. Treasury stock increased to 11.8 million shares at September 30, 2023 from 6.8 million at year-end 2022.
- In March 2023, the senior credit facility was amended to extend maturity to March 24, 2028 and transition from LIBOR to SOFR-based pricing. The company was in compliance with its debt covenants at September 30, 2023.
Guidance, Outlook, Risks and Unusual Items
- Management stated that it expects sales and earnings over the next twelve months to be sufficient to maintain compliance with the senior credit facility covenants and believes cash and available borrowings are sufficient to fund operations and capital expenditures for the foreseeable future. The filing does not provide a specific revenue or earnings forecast.
- The company expects to resume manufacturing at the Boston facility by late in the fourth quarter of 2023, but states that the timing and FDA acceptance of remediation efforts are uncertain. The company submitted a redesigned CereLink 510(k) application in September 2023 and expects U.S. shipments to resume after clearance; limited international shipments resumed in Q3.
- The FDA issued a July 2023 Warning Letter concerning quality-system issues at the Boston facility. Further regulatory action could restrict manufacturing, marketing or sales, and Class III premarket approvals related to the violations may be delayed until remediation is accepted.
- A securities class-action complaint was filed in September 2023 concerning alleged disclosures about Boston quality-system issues, remediation efforts and Tissue Technologies forecasts. The company says it has strong defenses and intends to defend the matter vigorously; the filing does not provide a clear estimate of potential loss.
- Contingent consideration liabilities totaled $82.7 million at September 30, 2023, including $64.2 million related to Surgical Innovation Associates. Future payments depend on revenue milestones and FDA approval of DuraSorb applications.
- The company performed its annual qualitative goodwill and indefinite-lived intangible impairment review and reported no indication of impairment. It also reported no impairment of specified Boston-related definite-lived intangibles after interim testing.
- Future amortization expense is estimated at approximately $20.7 million for the remainder of 2023, $82.2 million in 2024 and $82.1 million in 2025, based on quarter-end exchange rates.
- Key ongoing risks include FDA and other regulatory compliance, the Boston recall and manufacturing transition, CereLink remediation, product liability and litigation, supply-chain and inflationary pressures, foreign-currency movements, variable-rate debt and execution of acquisitions and restructuring initiatives.
Important Facts for Investors to Verify
- Progress toward FDA acceptance of Boston remediation, restart of manufacturing and resolution of the voluntary recall.
- Status and timing of the redesigned CereLink 510(k) review and any related provisions or lost sales.
- Recovery of Tissue Technologies revenue and margins excluding recall, divestiture and acquisition effects.
- Liquidity after the $275.0 million of share repurchases, the $75.7 million securitization-facility balance due May 28, 2024 and the 2025 convertible notes.
- Compliance with leverage covenants and the effect of SOFR-based borrowing costs after the credit-facility amendment.
- Potential cash payments and earnings volatility from acquisition-related contingent consideration, particularly SIA and ACell milestones.
- Developments in the Pembroke securities litigation and any additional FDA, product-liability or quality-system proceedings.